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 Editorial 
 Cytochrome P450 enzymes 
 Urs A.  Meyer 
 One consequence of the devotion of this journal to drug 
metabolism and the mechanisms by which drugs interact with 
each other is that cytochrome P450 enzymes (CYPs) will fi g-
ure prominently in its contents. This is because CYPs consti-
tute the predominant enzyme system for the metabolism of 
drugs and are the site of the majority of drug - drug interac-
tions. A series of reviews of current knowledge of the major 
drug metabolizing CYPs is therefore planned. 
 CYP genes are found in all species, from bacteria to fungi 
and from plants to animals. The CYP superfamily presently 
consists of more than 11,000 genes and the fi rst or ancestral 
 CYP gene probably dates back in evolution to 3.5 billion 
years ago. CYP proteins are named based on their evolution-
ary relationship and arranged into families and subfamilies 
on the basis of percentage amino acid sequence identity. The 
human genome harbors 57  CYP genes, arranged in 18 fami-
lies and numerous subfamilies ( http://drnelson.uthsc.edu/
CytochromeP450.html ). Only three of these families (CYP1, 
2 and 3) are involved in the metabolism of drugs and other 
xenobiotics. In fact, 10 human CYPs from seven subfamilies, 
namely CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5, 
are responsible for the metabolism of most drugs. The 
metabolism of drugs by these subfamilies is of varying impor-
tance. According to recent estimates, CYP3A4/5 contributed 
to the metabolism of 37 % of the 200 most frequently pre-
scribed drugs, followed by CYP2C9 (17 % ), CYP2D6 (15 % ), 
CYP2C19 (10 % ), CYP1A2 (9 % ), CYP2C8 (8 % ), CYP2B6 
(4 % ), CYP2A6 and CYP2E1 (  2 % )  (1) . Most other human 
CYPs are involved in the metabolism of endogenous mol-
ecules, including steroids, bile acids, fatty acids, prostaglan-
dins, leukotrienes, vitamin D, biogenic amines and retinoids. 
CYPs also metabolize nutritional components (e.g., from 
plants, fungi and food additives) and innumerable environ-
mental pollutants (e.g., polycyclic hydrocarbons, arylamines 
and herbicides). Most of the drug-metabolizing CYPs also 
have known or suspected endogenous substrates, such as ste-
roids, bile acids, fatty acids, food components, etc. This may 
lead to interactions between endogenous physiological and 
exogenous molecules and also lead to so-called endo-xeno-
biotic crosstalk  (2) . 
 In principle, CYP enzymes can thus metabolize thousands 
of chemicals. A CYP may have a rather strict catalytic speci-
fi city (e.g., in steroid or arachidonic acid metabolism) or be 
the catalyst for the oxidation of more than 100 drugs (e.g., 
CYP3A4). A hallmark of the substrate specifi cities of CYPs 
is that they are  “ overlapping ” . One drug may be metabo-
lized by several different CYPs, in spite of the regional- and 
stereoselectivity of the oxidative reactions occurring, and 
many different drugs may be metabolized by the same CYP. 
Recent advances in understanding of the structure - function 
relationship of the reaction mechanism, helped by the crystal 
structures of 12 mammalian CYPs, can explain many of the 
characteristics of these fascinating enzymes. 
 CYPs are a major source of inter- and intraindividual vari-
ation in drug response. Concomitant drug therapy, diet and 
lifestyle choices (e.g., whether someone smokes or drinks) 
but also disease (e.g., infl ammation) have important effects 
on the expression of CYP enzymes and cause drug - drug 
interactions. In particular, members of the  CYP1A ,  CYP2B , 
 CYP2C and  CYP3A gene subfamilies are highly inducible by 
some drugs and xenobiotics. This induction usually is tissue-
specifi c, rapid, dose-dependent, and reversible upon removal 
of the inducer. The molecular mechanisms by which exog-
enous and endogenous inducer substances bind to receptors 
like the cytosolic aromatic hydrocarbon receptor, constitutive 
androstane receptor and pregnane X receptor, and how this 
triggers a signaling cascade leading to the increased transcrip-
tion of CYPs and many other genes (including other drug-
metabolizing enzymes and transporters) is now relatively 
well-known  (3) . 
 Since one P450 enzyme may bind many different substrates, 
competition at the site of drug binding by co-substrates or 
other chemicals may cause inhibition, which is another source 
of drug - drug interactions. A certain drug may thus be an 
inhibitor and an inducer (e.g. ritonavir). 
 Age, gender, genetic and disease factors can produce addi-
tional considerable variability in CYP expression among (and 
within) individuals. One well-known major source of inter-
individual variability in drug disposition is genetic polymor-
phism of CYPs. Many allelic variants exist with most CYPs, 
resulting in genetically-determined pharmacological diversity 
between individuals  (1, 4) . A database of human allelic vari-
ants of  CYP genes is freely available on the internet and is 
continuously updated ( http://www.imm.ki.se/CYPalleles/ ). 
 Characterization of human drug-metabolizing enzymes 
and drug transporters has seen major progress in the past 
few years. As always, however, many questions regarding 
the function and regulation of CYPs remain unresolved. Of 
much recent interest are the infl uence of circadian rhythms 
 (5) , of the intestinal microbiome  (6) , and epigenetic and 
small RNA regulation of CYPs  (7) . I am looking forward to 
the series of articles on CYPs to learn more about all these 
issues. 
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